Press release
HR+ HER2-ve Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore our latest breakthroughs in HR+ HER2-ve Breast Cancer Research. Learn more about our innovative pipeline today! @ HR+ HER2-ve Breast Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the HR+ HER2-ve Breast Cancer Pipeline Report
* In February 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer.
* DelveInsight's HR+ HER2-ve Breast Cancer pipeline report depicts a robust space with 50+ active players working to develop 53+ pipeline therapies for HR+ HER2-ve Breast Cancer treatment.
* The leading HR+ HER2-ve Breast Cancer Companies such as Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
* Promising HR+ HER2-ve Breast Cancer Therapies such as TQB3616 capsule, NTQ1062 with Fulvestrant, Pembrolizumab, Sacituzumab Govitecan, Dapagliflozin 10Mg Tab, SM-88, VS-6766, Abemaciclib , and others.
Stay informed about the cutting-edge advancements in HR+ HER2-ve Breast Cancer treatments. Download for updates and be a part of the revolution in care @ HR+ HER2-ve Breast Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HR+ HER2-ve Breast Cancer Emerging Drugs Profile
* Camizestrant: AstraZeneca
Camizestrant is a potent, next-generation oral SERD and pure ER antagonist, that has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations. The asset has been shown to promising anti-tumour profile when administered alone or in combination with palbociclib and thus, the company is running a Phase III trial for the same.
* Dato-DXd: Daiichi Sankyo, Inc.
Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive, HER2- negative breast cancer. It is a TROP2 directed antibody drug conjugate (ADC) designed using Daiichi Sankyo's proprietary DXd ADC technology, datopotamab deruxtecan is one of the three lead ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in AstraZeneca's ADC scientific platform. Datopotamab deruxtecan is comprised of a humanized anti-TROP2 IgG1 monoclonal antibody, developed in collaboration with Sapporo Medical University, attached to a number of topoisomerase I inhibitor payloads, an exatecan derivative, via tetrapeptide-based cleavable linkers.
* CX-2009: CytomX Therapeutics
CX-2009 is a Probody drug conjugate that consists of a humanized anti-CD166 monoclonal antibody conjugated to DM4, a potent microtubule inhibitor known to be active against multiple cancer types. It is currently being tested in Phase II trial in Advanced HR-Positive/HER2-Negative Breast Cancer and of Praluzatamab Ravtansine as Monotherapy and in Combination with Pacmilimab (CX-072) in Advanced Triple-Negative Breast Cancer.
* RGT-419B: Regor Therapeutics
RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. The clinical development program of RGT-419B is designed to address the unmet medical needs of patients who are refractory or have relapsed after previous treatment, providing new opportunities to improve survival and quality of life for patients with advanced/metastatic breast cancer. It is currently being tested in Phase I trial in in subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer.
Learn more about HR+ HER2-ve Breast Cancer Drugs opportunities in our groundbreaking HR+ HER2-ve Breast Cancer Research and development projects @ HR+ HER2-ve Breast Cancer Unmet Needs [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
HR+ HER2-ve Breast Cancer Companies
Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
HR Positive/ HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
HR+ HER2-ve Breast Cancer Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Discover the latest advancements in HR+ HER2-ve Breast Cancer treatment by visiting our website. Stay informed about how we're transforming the future of disease @ HR+ HER2-ve Breast Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the HR+ HER2-ve Breast Cancer Pipeline Report
* Coverage- Global
* HR+ HER2-ve Breast Cancer Companies- Regor Therapeutics, Seagen Inc., CytomX Therapeutics, Taizhou EOC Pharma, Chia Tai Tianqing Pharmaceutical Group, AstraZeneca, Daiichi Sankyo, Inc., Tyme, Inc., Context Therapeutics, Eisai Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Simcere Pharmaceutical Co., Kind Pharmaceuticals, Merus N.V., Atossa Therapeutics, Roche and others.
* HR+ HER2-ve Breast Cancer Therapies- TQB3616 capsule, NTQ1062 with Fulvestrant, Pembrolizumab, Sacituzumab Govitecan, Dapagliflozin 10Mg Tab, SM-88, VS-6766, Abemaciclib , and others.
* HR+ HER2-ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* HR+ HER2-ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of HR+ HER2-ve Breast Cancer Pipeline on our website @ HR+ HER2-ve Breast Cancer Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/hr-positive-her2-negative-breast-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* HR Positive/ HER2 Negative Breast Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* HR Positive/ HER2 Negative Breast Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Dato-DXd: Daiichi Sankyo, Inc.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CX-2009: CytomX Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* RGT-419B: Regor Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* HR Positive/ HER2 Negative Breast Cancer- Unmet Needs
* HR Positive/ HER2 Negative Breast Cancer- Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hr-her2ve-breast-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HR+ HER2-ve Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 3883997 • Views: …
More Releases from ABNewswire
BetterSleep Named Best Sleep App for 2026 by Canadian Journalists
Image: https://www.abnewswire.com/upload/2025/12/5495843404876a43fa9615afcae43616.jpg
In a comprehensive evaluation of sleep technology, top Canadian journalists and reporters working for 514Blog have voted BetterSleep as the best sleep app for 2026. After rigorously testing dozens of sleep applications across multiple criteria including user experience, scientific backing, content variety, and effectiveness, the 514Blog editorial team unanimously selected BetterSleep for its exceptional combination of evidence-based sleep science, extensive sound library, and personalized sleep improvement features. The app's…
GlowRow's Unplanned Spotlight at San Antonio's Holly Jolly Kayaking Event Captur …
Image: https://www.abnewswire.com/upload/2025/12/c7c9ffa8bc844937e29cd958d7cead51.jpg
San Antonio, TX - At the San Antonio River Authority's sold-out Holly Jolly Kayaking event, four GlowRow Registered team members secured public tickets like everyone else and slipped quietly into the water. No fanfare. No announcement. No stage set for impact, just four clear kayaks joining a community paddle beneath the holiday lights.
But the Riverwalk has a way of noticing things that aren't trying to be noticed.
As the GlowRow…
The Critic Magazine: BBC Strictly Losing Its Rhythm
The BBC's flagship entertainment show, Strictly Come Dancing, has been a long-standing beacon of success for the broadcaster, a sparkling remedy to the autumn blues. However, as the 21st season kicks off, there are growing concerns about whether the ballroom giant is losing its rhythm.
Once a guaranteed hit, Strictly has faced a difficult few years. Reports of behind-the-scenes tensions and viral memes have occasionally tested its squeaky-clean image. For a…
SK Law Office's H.E. Samantha Yem Calls on ASEAN Leaders to Place Health Justice …
H.E. Samantha Yem, Founder and President of SK Law Office and Advisor to the Royal Government of Cambodia, today urged ASEAN governments to make health justice a central pillar of national development, delivering a keynote address at the Knowledge Lab for Innovation Community (KLIC) 2025 in Hanoi.
"Health justice is not charity - it is a legal protection owed to every person," Yem said. "No nation can achieve sustainable prosperity with…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
